Advancing Breast Cancer Options
Ki-67 offers significant insight to assess risk and inform treatment in early breast cancer (EBC), and fully understanding risk of recurrence in EBC is vital to inform disease management. Identifying patients at high risk can facilitate treatment decisions to potentially improve outcomes.
Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is indicated as an aid in identifying patients with EBC at high risk of disease recurrence for whom adjuvant treatment with Verzenio® in combination with endocrine therapy is being considered.
Agilent Technologies continues to lead with innovation, quality, and ease of implementation, and Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is comprised of quality components, seamlessly connected for reliable integration into your lab.